Also, early recognition is key to preserving unnecessary operation or other intervention. Key Word(s): 1. liver cirrhosis; 2. intramuscular hematoma; 3. outcome; 4. treatment Table 1 Intramuscular hematoma in patients with liver cirrhosis Case Age Gender Etiology Location Treatment Outcom Child-Pugh score Case A–C: Our Patients; Case 1–8 Previous repoted patients; HCV: Hepatitis C virus;TAE: Transcatheter arterial embolism Presenting Author: SULAIMAN BUDIMAN SUJATMIKA Additional Authors: RINO A GANI, C RINALDI A LESMANA, MARCELLUS SIMADIBRATA, Atezolizumab clinical trial ENING KRISNUHONI, ALI SULAIMAN Corresponding Author: BUDIMAN SUDJATMIKA Affiliations:

Cipto Mangunkusumo Hospital, Cipto Mangunkusumo Hospital, Cipto Mangunkusumo Hospital, Cipto Mangunkusumo Hospital, Cipto LGK-974 solubility dmso Mangunkusumo Hospital Objective: Chronic hepatitis B (CHB) infection is still a major problem in most Asian countries. The role of seromarkers such as quantitative HBV DNA and quantitative HBsAg might not predict accurately the intrahepatic viral activity. Intrahepatic cccDNA and Pregenomic RNA measurement is not practical in clinical practice. Quantification of intrahepatic HBsAg might give a better prediction in clinical practice since the liver biopsy is also a common procedure for the liver

condition assessment. To know the clinical significance of intrahepatic HBsAg measurement in correlation with quantitative HBsAg serum in CHB patients who received oral antiviral therapy. Methods: This was a retrospective cohort study using liver specimens and blood samples from 26 CHB patients who underwent oral antiviral therapy for one year (2010–2011) from two big referral hospitals (Cipto Mangunkusumo Hospital

and Medistra Hospital). Quantification of HBsAg particles in the liver specimens was done by immunohistochemistry staining. Other data was obtained from the patient’s database. Statistical analysis was done using SPSS ver. 17. Results: There was a weak correlation between quantitative HBsAg serum with intrahepatic HBsAg particles before and after one year ADP ribosylation factor oral antiviral therapy (r = −0.20, p .249; r = 0.15, p .433). Quantitative HBsAg serum was decreased after one year oral antiviral therapy, however there was no mean difference in intrahepatic HBsAg particles after one year oral antiviral therapy (p .468). Conclusion: Intrahepatic viral activity might not be accurately predicted by seromarkers as quantitative HBsAg serum is more related to viral load but intrahepatic HBsAg particles reflects more intrahepatic viral activity that many factors could influence this condition. Further study is needed with larger samples to confirm these findings.